Androxal enclomiphene: Phase IIb started

Repros began a double-blind, placebo-controlled, U.S. Phase IIb trial to evaluate 12.5 and 25 mg Androxal enclomiphene in up to 150 patients with secondary hypogonadism or adult-onset idiopathic hypog...